Quantcast

Latest KemPharm Inc. Stories

2014-09-30 08:32:31

KemPharm's Intellectual Property Estate Now Includes Composition of Matter Patents for Two Ligand Activated Technology (LAT) Opioid Prodrugs - KP511 and KP201 CORALVILLE, Iowa, Sept. 30, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,816,083 to KemPharm...

2014-09-23 08:31:03

KemPharm Joins CLADD in Support of Legislation from Health Canada to Encourage More Responsible Development and Administration of Prescription Opioids CORALVILLE, Iowa, Sept. 23, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it received a No Objection Letter (NOL) from Health Canada to begin clinical trials in Canada for its lead...

2014-09-08 08:30:58

Studies to Investigate Ability of KP201 to Deter Abuse and Reduce Opioid-Induced Constipation CORALVILLE, Iowa, Sept. 8, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the initiation of clinical trials of KP201 designed to investigate the drug candidate's ability to deter abuse and reduce opioid-induced constipation. KP201 (benzhydrocodone hydrochloride...

2014-08-06 12:29:09

CORALVILLE, Iowa, Aug. 6, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Canaccord Genuity 34(th) Annual Growth Conference at the InterContinental Boston Hotel in Boston, MA. Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's clinical, regulatory and...

2014-06-03 08:32:29

Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent Prodrugs CORALVILLE, Iowa, June 3, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has entered into a $60 million financing agreement with an investment fund managed by...

2014-04-30 12:30:02

Patent Protection for KP511 Extends KemPharm's Intellectual Property Estate for Leading Franchise of Abuse-Deterrent Opioid Medications CORALVILLE, Iowa, April 30, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Benzoic...

2014-03-04 08:32:42

Composition of Matter Patents Issued in Multiple Countries for KemPharm's Lead Abuse-Deterrent Hydrocodone Prodrug CORALVILLE, Iowa, March 4, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that multiple global composition of matter patents have been issued for KP201 in Russia, Ukraine, Kazakhstan, Japan, Australia, New Zealand and South Africa....

2014-02-26 08:29:29

CORALVILLE, Iowa, Feb. 26, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Cowen and Company 34(th) Annual Health Care Conference at the Boston Marriott Copley Place in Boston, MA. Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline,...

2014-02-05 08:29:57

CORALVILLE, Iowa, Feb. 5, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D., will present at the 16(th) Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 16(th) Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New...

2014-01-13 12:26:59

Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President - General Counsel for Stine Seed Company, Added to KemPharm's Board CORALVILLE, Iowa, Jan. 13, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the appointment of Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President - General Counsel, Stine Seed...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.